Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia.

por Petra Kövy, Zoltán Őrfi, András Bors, András Kozma, László Gopcsa, János Dolgos, Nóra Lovas, József Harasztdombi, Viktor Lakatos, Ágnes Király, Gábor Mikala, István Vályi-Nagy, Péter Reményi, Hajnalka Andrikovics
Publicado 2021

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS

por Mehmut TURGUT, Roman HAJEK, Tomas JELÍNEK, Philippe MOREAU, Thomas MARTIN, Ludek POUR, Gabor MIKALA, Argiris SYMEONIDIS, Sara BRINGHEN, Andreea RAWLINGS, Marie Laure RISSE, Helgi VAN DE VELDE, Ivan SPICKA
Publicado 2021